How much weight do people lose on GLP-1 drugs?

In clinical trials, semaglutide (Wegovy) produces around 15 percent body weight loss, and tirzepatide (Zepbound) around 20 percent, both over 72 weeks combined with diet and exercise. Real-world results vary widely.

What are the most common side effects of Ozempic and Mounjaro?

Nausea, vomiting, diarrhea, and constipation are the most common, especially during dose escalation. Most side effects subside after 4 to 8 weeks. Serious side effects are rare but include pancreatitis and gastroparesis.

Do you have to take GLP-1 drugs forever?

Current evidence suggests most people regain weight within a year of stopping. GLP-1s appear to be a long-term medication for most patients, similar to blood pressure or cholesterol drugs.

What happens when you stop taking semaglutide?

Appetite returns within weeks, and most people regain 50 to 100 percent of lost weight within 12 months without other interventions. Tapering is sometimes used but does not prevent regain.

GLP-1 Drugs 2026: Ozempic, Mounjaro & Wegovy Complete Guide

The GLP-1 Revolution in 2026

GLP-1 receptor agonists have evolved from niche diabetes drugs to some of the most prescribed medications in the world. In 2026, more than 50 million Americans have used or are currently using a GLP-1 medication, and the drug class has been studied for uses far beyond diabetes and weight loss.

This guide covers the current state of GLP-1 drugs: what's available, what they do, the costs, and what's coming next.

What Are GLP-1 Drugs?

GLP-1 (glucagon-like peptide-1) receptor agonists are medications that mimic a naturally occurring hormone in your gut. This hormone:

Slows stomach emptying (making you feel full longer)
Reduces appetite signals to the brain
Improves insulin response
Lowers blood sugar
May have direct effects on the heart, liver, and brain

The drug class was originally developed for Type 2 diabetes. The dramatic weight loss experienced by patients led to dedicated weight loss formulations and ongoing research into other conditions.

The Major GLP-1 Drugs in 2026

Semaglutide (Ozempic, Wegovy)

Manufacturer: Novo Nordisk
Approved for: Type 2 diabetes (Ozempic), weight loss (Wegovy)

Aspect	Details
Dosing	Once weekly injection (or oral for diabetes)
Weight loss	15% average in clinical trials
Cost (US, no insurance)	$900–$1,400/month
Common side effects	Nausea, vomiting, diarrhea, constipation
Serious risks	Pancreatitis, gastroparesis, possible thyroid C-cell tumors

Tirzepatide (Mounjaro, Zepbound)

Manufacturer: Eli Lilly
Approved for: Type 2 diabetes (Mounjaro), weight loss (Zepbound)

Aspect	Details
Dosing	Once weekly injection
Weight loss	21% average in clinical trials
Cost (US, no insurance)	$1,000–$1,500/month
Common side effects	Nausea, vomiting, diarrhea
Serious risks	Similar to semaglutide

Tirzepatide is a "dual agonist" — it activates both GLP-1 and GIP receptors, which may explain the slightly greater weight loss compared to semaglutide.

Retatrutide (Triple Agonist)

Manufacturer: Eli Lilly
Status: Phase 3 trials, expected approval 2026–2027

Aspect	Details
Dosing	Once weekly injection
Weight loss	24% average in Phase 2 trials
Cost	TBD
Side effects	Nausea, vomiting, GI issues

Retatrutide activates GLP-1, GIP, and glucagon receptors — a "triple agonist" approach that has shown the largest weight loss results to date in clinical trials.

Orforglipron (Oral GLP-1)

Manufacturer: Eli Lilly
Status: Phase 3 trials, expected approval 2026–2027

Aspect	Details
Dosing	Daily oral pill
Weight loss	14% average in Phase 2 trials
Cost	TBD
Side effects	Similar to injectable GLP-1s

Orforglipron is the most advanced oral GLP-1. If approved, it eliminates the need for weekly injections.

Drug Comparison

Drug	Dosing	Weight Loss	Diabetes	Heart Benefits
Semaglutide	Weekly injection or daily oral	15%	Yes	Yes
Tirzepatide	Weekly injection	21%	Yes	Yes
Retatrutide	Weekly injection	24% (Phase 2)	Yes	Being studied
Orforglipron	Daily oral	14% (Phase 2)	Yes	Being studied
Liraglutide (older)	Daily injection	8%	Yes	Yes
Exenatide (older)	Twice daily injection	5%	Yes	Limited

How Effective Are GLP-1 Drugs?

Weight Loss Trajectory

In clinical trials, GLP-1 drugs produce a predictable weight loss pattern:

Time	Weight Loss
Month 1	2–3% (mostly water)
Month 3	5–7%
Month 6	10–12%
Month 12	15–21%
Month 24	15–25% (continued)

Most weight loss occurs in the first 6–12 months, then plateaus. Continuing the medication is required to maintain weight loss — most patients regain 50–70% of lost weight within a year of stopping.

Who Should Take GLP-1 Drugs?

Strong candidates:
- BMI ≥30 (obesity)
- BMI ≥27 with weight-related conditions (diabetes, hypertension, sleep apnea, etc.)
- Type 2 diabetes
- Cardiovascular disease with obesity
- Sleep apnea with obesity

Less clear candidates:
- BMI 25–27 with no other risk factors
- Cosmetic weight loss
- Eating disorders (contraindicated)

Side Effects and Risks

Common Side Effects (60–80% of users)

Nausea (most common)
Vomiting
Diarrhea
Constipation
Abdominal pain
Decreased appetite
Headache
Fatigue

Most side effects are worst in the first 4–8 weeks and improve over time. Starting at a low dose and titrating up reduces side effects.

Serious Risks (Rare)

Pancreatitis: ~0.5% of users
Gastroparesis: Stomach paralysis, often temporary
Gallbladder disease: Higher risk with rapid weight loss
Thyroid C-cell tumors: Observed in rodents; human risk unclear
Suicidal ideation: FDA is investigating, no clear causal link
Vision changes: Including rare cases of NAION (eye stroke)

Long-Term Safety

The longest safety data extends 5+ years for semaglutide and tirzepatide. Beyond that, effects are unknown. Studies on cancer, bone density, and cognitive effects are ongoing.

The Cost Question

US Pricing (2026)

Without insurance, GLP-1 drugs cost $900–$1,500/month in the US — making them among the most expensive common medications.

Insurance Coverage

Coverage varies widely:

Insurance Type	Coverage Status
Medicare	Limited to diabetes indication
Medicaid	Varies by state
Private insurance	Increasingly common for diabetes and obesity
Employer plans	~40% cover, often with prior authorization
Self-pay (no insurance)	Available through manufacturer savings programs

Compounded Alternatives

Compound pharmacies can produce semaglutide and tirzepatide at lower cost, but with concerns about quality and safety. The FDA has issued warnings about compounded GLP-1s.

International Access

GLP-1 drugs are significantly cheaper in many countries:
- Canada: $200–$400/month
- Mexico: $150–$300/month
- UK (NHS): Free for qualifying patients
- Australia: Subsidized for diabetes

Medical tourism for GLP-1s has become common among US patients, though with risks.

Surprising Health Benefits Beyond Weight Loss

The 2026 research has uncovered benefits well beyond weight loss:

Cardiovascular

20% reduction in major cardiovascular events
Reduced heart attack and stroke risk
Improved blood pressure

Liver

80%+ reduction in liver fat (MASH/MASLD treatment)
FDA approval for MASH expected in 2026
First drug treatment for fatty liver disease

Brain

Reduced addictive behaviors (alcohol, opioids, gambling)
Possible neuroprotective effects (Alzheimer's, Parkinson's studies ongoing)
Improved sleep apnea
Possible benefits for depression

Kidney

24% reduction in kidney disease progression
Now being studied for chronic kidney disease

Joint Health

Reduced knee and hip pain in obese patients
Decreased need for joint replacement surgery

The Lifestyle Component

GLP-1 drugs work best combined with lifestyle changes:

1. Strength training — Prevents muscle loss during rapid weight loss
2. Adequate protein intake — 1.0–1.6g per kg of body weight
3. Prioritizing sleep — 7–9 hours per night
4. Mindful eating — Drugs reduce appetite but food choices matter
5. Hydration — Important for managing side effects

What Happens When You Stop?

This is one of the most important questions in 2026. Studies show:

50–70% weight regain within 12 months of stopping
Appetite returns to pre-medication levels
Metabolic adaptation makes maintaining weight harder
Most patients who stop the drug return to their original weight within 2 years

This has raised questions about whether GLP-1s are a "lifetime commitment" for those who start them.

What's Coming Next

Near-Term Pipeline (2026–2028)

Retatrutide: Triple agonist with 24% weight loss
Orforglipron: First highly effective oral GLP-1
CagriSema: Combination of semaglutide with amylin analog
Multiple oral formulations: Currently in trials

Long-Term Pipeline (2028–2030)

GLP-1 + amylin combinations: For enhanced weight loss
Cardiovascular-specific formulations: For heart patients
Neurodegeneration treatments: For Alzheimer's and Parkinson's
GLP-1 biosimilars: Lower-cost generic versions

Frequently Asked Questions

Are GLP-1 drugs safe long-term?
Long-term safety data extends 5+ years. Beyond that, effects are being studied. Current data suggests acceptable safety for appropriate patients.

Will my insurance cover GLP-1 drugs?
Coverage varies by insurance plan, indication, and prior authorization requirements. Many employer plans cover for diabetes and increasingly for obesity.

How much weight will I lose?
Average 15–21% body weight on semaglutide or tirzepatide. Retatrutide may reach 24%+. Individual results vary significantly.

Can I drink alcohol on GLP-1 drugs?
Alcohol is not contraindicated but may worsen nausea, dehydration, and blood sugar. Many people report reduced desire to drink.

Do I need to diet while on GLP-1 drugs?
Yes, but the drug makes it easier. Prioritize protein, vegetables, and whole foods. Avoid greasy, fried, or high-sugar foods that worsen GI side effects.

Are compounded GLP-1s safe?
Quality varies significantly. Compounded semaglutide from reputable 503A pharmacies is generally safe. Avoid "research chemical" or unverified sources.

Will GLP-1 drugs be cheaper in the future?
Yes. Patent expirations (semaglutide in 2031, tirzepatide in 2036) and increasing competition will drive prices down. Biosimilars from Indian and Chinese manufacturers are already in development.